Skip to main content
. 2012 Jun 26;20(9):1664–1675. doi: 10.1038/mt.2012.56

Figure 8.

Figure 8

SFV-IL-12 + anti-CD137 combined therapy up-regulates CD137 on CD8+ T cells and reduces anti-SFV humoral immune responses. (a–c) B16-OVA tumor-bearing mice were treated intratumorally with saline or 108 viral particles (vp) of SFV-LacZ or SFV-IL-12 on day 7. The same day mice received intraperitoneally 100 µg of rat immunoglobulin G (IgG) or anti-CD137 mAb. Two days later, mice were sacrificed and tumor nodules and draining lymph nodes (DLNs) were processed and analyzed by flow cytometry. (a) Plots showing CD137 expression level on CD8+ T cells from tumor nodules. (b,c) Graphs showing the percentage of CD8+ T cells that upregulate CD137 expression on their surface in tumor nodules or DLNs, respectively. (d) B16-OVA tumor-bearing mice treated with SFV-IL-12 + rat IgG, or anti-CD137 mAb, as described in Figure 1, were bled at day 21 and sera samples were analyzed to determine anti-SFV neutralizing antibody titers. The results are represented as mean ± SEM. *P < 0.05; **P < 0.01. α, anti-; SFV-IL-12, Semliki Forest virus encoding interleukin-12.